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Intrahepatic Injection of Recombinant Adeno-Associated 
Virus Serotype 2 Overcomes Gender-Related Differences 
in Liver Transduction
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ABSTRACT
The liver is an attractive organ for gene therapy because of its important role in many inherited and acquired
diseases. Recombinant adeno-associated viruses (rAAVs) have been shown to be good candidates for liver gene
delivery, leading to long-term gene expression. We evaluated the influence of the route of administration on
rAAV-mediated liver transduction by comparing levels of luciferase expression in the livers of male and fe-
male mice after injection of rAAV serotype 2, using three different routes of administration: intravenous (IV),
intraportal (IP), or direct intrahepatic (IH) injection. To determine transgene expression we used a noninva-
sive optical bioluminescence imaging system that allowed long-term in vivo analysis. After IV injection dra-
matic differences in liver transgene expression were observed, depending on gender. When IP injection was
used the differences were reduced although they were still significant. Interestingly, direct intrahepatic in-
jection of rAAV vectors was associated with the fastest and strongest onset of luciferase expression. More-
over, no gender differences in liver transduction were observed and luciferase expression was confined to the
site of injection. Thus, direct intrahepatic injection of rAAV offers specific advantages, which support the po-
tential of this route of administration for future clinical applications.
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INTRODUCTION
ADENO-ASSOCIATED VIRUSES are small, single-stranded DNAviruses derived from a replication-deficient member of the
parvovirus family and do not appear to cause any disease in hu-
mans (Lai et al., 2002). Recombinant adeno-associated vectors
(rAAVs) are safe and effective gene therapy vectors. They are
not pathogenic, do not elicit significant immune responses,
transduce both quiescent and dividing cells, and can provide
high-level and long-term transgene expression (Lai et al., 2002;
Bessis et al., 2004; Buning et al., 2004). Furthermore, it has
been described that rAAV integration is inefficient and the per-
sistence of rAAV genomes in tissues is largely due to episomal
genomes (Nakai et al., 2001; McCarty et al., 2004). Many of
their biological properties make AAV an attractive gene trans-
fer system for clinical application.
AAV particles enter the cell via receptor-mediated endocy-
tosis through clathrin-coated pits. Inside the cells and after en-
dosomal acidification, the virus is released into the cytosol. Upon
release into the cytosol, it accumulates perinuclearly and slowly
penetrates into the nucleus. Once in the nucleus, the transfec-
tion efficiency is further limited by the need to convert the sin-
gle-stranded (ss) genome into double-stranded (ds), transcrip-
tionally active forms (Bartlett et al., 2000). Depending on the
cell type, dsDNA conversion occurs by de novo synthesis of the
second strand or through annealing of complementary plus and
minus single-stranded molecules (Nakai et al., 2000).
Recombinant AAVs show some degree of liver specificity
after systemic injection (Summerford et al., 1999), and have
been proved to be highly effective vehicles for gene therapy in
several disorders such as glycogen storage disease type II (Sun
et al., 2005), hemophilia (High, 2002; Wang et al., 2005),
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phenylketonuria (PKU) (Mochizuki et al., 2004), and hyperc-
holesterolemia (Lebherz et al., 2004). They have been suc-
cessfully used to transduce factor IX to mouse, dog, and non-
human primate livers and have achieved persistent, curative
concentrations of the functionally active molecule (Snyder et
al., 1997; Summerford et al., 1999; Harding et al., 2004; Wang
et al., 2005). rAAV vectors are currently being evaluated in pa-
tients with hemophilia (High, 2004). The routes of administra-
tion for rAAV most frequently used to transduce the liver are
intravenous injection and portal vein infusion (Harding et al.,
2004). AAV administration by hepatic arterial infusion resulted
in highly efficient liver transduction (Ohashi et al., 2005). In
mice, injection into the splenic capsule has been used to effi-
ciently deliver the AAV vector to the portal circulation (Daly,
2004). Direct intrahepatic injection has been used in fetuses
(Mitchell et al., 2000) and in adult female mice (Snyder et al.,
1997). Intrahepatic injection of an AAV expressing factor IX
resulted in high levels of protein expression; however, liver
transduction by this route has not been characterized (Snyder
et al., 1997).
Striking differences in liver transduction have been reported
after portal vein injection of rAAV serotypes 2 and 5, depend-
ing on the sex of the animal (Davidoff et al., 2003). Further-
more, in a mouse model of PKU, about three times more rAAV
must be injected into female mice than into male mice to achieve
an equivalent reduction in serum phenylalanine (Mochizuki et
al., 2004). These data have been further corroborated by our
results in woodchucks chronically infected with the woodchuck
hepatitis virus, in which the intraportal administration of rAAV
carrying the woodchuck interferon- (IFN-) gene resulted in
dramatic differences in cytokine expression depending on the
sex (Berraondo et al., 2005). This would seem to indicate that
sex differences in AAV-mediated liver transduction found in
mice are not species specific and may represent a problem in
clinical applications. Analysis of transgene expression in the
rodent brain after AAV injection into the thalamus indicates
that sex also influences AAV transduction efficiency in this or-
gan (Dodge et al., 2005).
The number of hepatocytes that are stably transduced, even
when high doses of rAAV vector are delivered, is relatively low
(Nakai et al., 2002; Sanlioglu et al., 2004; Zhong et al., 2004).
This might represent a problem when a large animal model is
used or when a gene therapy protocol is to be applied in a clin-
ical trial, because of the large amounts of recombinant vector
that would have to be administered. Therefore, we investigated
whether intrahepatic injection of rAAV might be superior to
other injection methods for safe and effective transduction of
the liver. Three different routes of administration targeting the
liver were used: intrahepatic (IH), intraportal (IP), and intra-
venous (IV, via the tail vein) injection. Levels of luciferase ex-
pression were then compared. The use of a noninvasive optical
bioluminescence imaging system allowed long-term quantita-
tive evaluation of transgene expression in living animals as well
as the study of vector biodistribution. During these analyses we
observed significant differences in AAV-mediated liver trans-
gene expression depending on the route of administration and
the gender of the animal. Direct intrahepatic injection of the
virus resulted in faster, stronger, and localized liver transduc-
tion and led to transgene expression levels in females compa-
rable to those in males injected by the IV or IP route.
MATERIALS AND METHODS
rAAV vector construction
Construction of AAV-Luc was performed as described
(Berraondo et al., 2005). Briefly, a fragment containing the lu-
ciferase cDNA was obtained by polymerase chain reaction
(PCR) from plasmid pCDNA2.1-Luc. Plasmid pGTC-wIFN-
WRE was digested with EcoRI to obtain the expression cas-
sette without wIFN and was treated with T4 DNA polymerase
to create blunt ends. Both fragments were ligated to obtain the
plasmid pGTC-Luc-WRE. The expression cassette from this
plasmid was obtained by digestion with SpeI and SalI and
cloned into the plasmid pAAV-Luc. This plasmid was digested
with XbaI and SalI and both fragments were ligated. This plas-
mid was transformed into Escherichia coli strain SURE (Strat-
agene, La Jolla, CA) and the integrity of viral inverted termi-
nal repeats (ITRs) was confirmed by digestion with PvuII, SmaI,
and SnaBI.
rAAV vector production and purification
Plasmid with the expression cassette flanked with ITRs and
helper plasmid pDG (Zhong et al., 2004) were prepared with
an EndoFree plasmid mega kit (Qiagen, Valencia, CA). A mix-
ture of plasmid (20 g of AAV plasmid and 55 g of pDG per
plate) was transfected into 293T cells, using linear poly-
ethylenimine (25 kDa; Polysciences, Warrington, PA) as de-
scribed in Durocher et al. (2002). After 48 hr cells were har-
vested, resuspended in Dulbecco’s modified Eagle’s medium
(DMEM; 2.5 ml/plate), and lysed by two freeze–thaw cycles.
Virus was digested with 0.1 mg each of DNase and RNase (both
from Roche Diagnostics, Mannheim, Germany) for 30 min at
37°C and centrifuged for 15 min at 4°C at 3000 rpm. The su-
pernatant was treated with 0.5% deoxycholic acid (Sigma, St.
Louis, MO) for 30 min at 37°C. It was then clarified by filtra-
tion through a 0.22-m filter and the virus was loaded into a
HiTrap heparin column (Amersham Biosciences, Uppsala,
Sweden) that had been equilibrated with phosphate-buffered
saline (PBS, pH 7.4; GIBCO, Paisley, UK) at 1 ml/min. The
matrix was washed with 25 ml of PBS–0.1 M NaCl and virus
was eluted with 15 ml of PBS with 0.4 M NaCl. To exchange
the buffer and to concentrate the virus, it was applied to an 
ULTRAFREE-15 centrifugal filter device (Millipore, Bedford,
MA), using PBS-MK (PBS containing 1 mM MgCl2 and 
2.5 mM KCl).
For titration an aliquot was digested with DNase and treated
with proteinase K (Roche Diagnostics). After inactivation, the
titer was determined by real-time PCR. Primers and TaqMan
probes (Applied Biosystems, Foster City, CA) were designed
to amplify a fragment of the luciferase gene, using Primer Ex-
press software (Applied Biosystems). Primers and probe were
as follows: sense, 5-AACATAAAGAAAGGCCCGGC-3; an-
tisense, 5-GCCTTATGCAGTTGCTCTCCA-3; probe, 5-
CATTCTATCCGCTGGAAGATGGAACCG-3.
The reaction was performed in 20 l with 2 l of sample, 
2 l of reaction mix (LightCycler FastStart DNA Master hy-
bridization probes; Roche Diagnostics, Basel, Switzerland), 
3.2 l of MgCl2 (25 mM), 0.6 l of each primer (10 mM), and 
0.4 l of probe (5 mM). PCR was performed according to the
following parameters: 10 min at 95°C (denaturation) and 40 cy-
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cles of 0.1 sec at 95°C and 20 sec at 60°C (hybridization/elon-
gation). The fluorescence signal delivered during PCR ampli-
fication was monitored with the LightCycler system (Roche Di-
agnostics). The titer was expressed as viral genomes (VG) per
milliliter.
Mice and AAV administration
BALB/c or C57BL/6 mice were obtained from Harlan
(Barcelona, Spain), housed under specific pathogen-free con-
ditions, and handled according to the guidelines of our institu-
tion (Centro de Investigación Farmacobiológica Aplicada, Pam-
plona, Spain).
AAV administration was performed in 8-week-old mice. For
intrahepatic and intraportal injection, mice were anaesthetized
with ketamine–xylazine and a partial laparotomy was per-
formed. Mice received a direct injection of 50 l of rAAV virus
into the left medial lobe of the liver or into the spleen. Intra-
venous injection was performed by injecting a total volume of
200 l through the tail vein.
Bioluminescence measurement in living mice
Mice were anesthetized with ketamine–xylazine and 100 l
of D-luciferin (Xenogen, Alameda, CA) at a concentration of
30 mg/ml, diluted in 150 mM NaCl solution, was injected by
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FIG. 1. Short-term in vivo CCD signal intensity in the liver of BALB/c mice injected with low-dose AAV-Luc. Male and fe-
male BALB/c mice were injected with AAV serotype 2 expressing luciferase gene, at a dose of 2.5  1010 genome-containing
particles. AAV-Luc was injected intravenously (IV; n  8 males and 8 females), intraportally (IP; n  3 males and 3 females),
or intrahepatically (IH; n  8 males and 8 females). Subsequent imaging was performed for luciferase expression, using D-lu-
ciferin injected intraperitoneally (150 mg/kg) and starting on day 1 and every week thereafter. Total bioluminescence was quan-
tified and plotted over time. Each dot represents the decimal logarithm of bioluminescence for each animal at a time point. A
solid line shows the mean value of each group; dashed lines indicate the confidence interval.
the intraperitoneal route. The animals were placed in the imag-
ing chamber of the Xenogen IVIS system (Xenogen), which in-
cludes a cooled charge-coupled device (CCD) camera. A gray-
scale photograph of the animals was acquired, followed by
bioluminescence acquisition. Regions of interest (ROIs) were
drawn over the positions of greatest signal intensity on each an-
imal, as well as over regions of “no” signal, which were uses
as background readings. Light intensity was quantified as pho-
tons/sec/cm2/sr. The gray-scale photograph and data images
from all studies were superimposed, using Living Image
(Xenogen).
For the ex vivo analysis of luciferase expression, animals
were killed on day 92 after AAV-Luc injection and various or-
gans were collected and frozen in liquid nitrogen. The organs
collected were as follows: testicles or ovaries, spleen, stomach,
lungs, heart, kidney, and liver (separated into left medial lobe,
right medial lobe, and right lateral lobe). Tissue samples were
homogenized in 1 lysis buffer and the protocol to detect lu-
ciferase in cells (Promega, Madison, WI) was followed.
Data analysis
All data were analyzed with nonlinear mixed effect models,
using MONOLIX software (http://www.math.u-psud.fr/
lavielle/monolix/). Selection between models was based on the
precision of the estimated parameters, goodness-of-fit plots, and
the value of the Akaike information criterion (AIC). The model
with the lowest AIC value was selected, because it indicates
that precision of model parameters and data description was ad-
equate (Ludden et al., 1994).
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TABLE 1. Lmax AND T50 VALUES FROM BALB/c MICE TRANSFER WITH 2.5  1010 VG OF AAV-Luc
Female Male
IV [M (SD)] IP [M (SD)] IH [M (SD)] IV [M (SD)] IP [M (SD)] IH [M (SD)]
Lmax 1.46 (0.13) 2.64 (0.32) 3.26 (0.23) 3.21 (0.53) 3.38 (0.13) 3.80 (0.24)
T50 (days) 5.92 (0.03) 4.35 (0.13) 2.39 (0.24) 5.95 (0.18) 4.14 (0.10) 2.35 (0.21)
Abbreviations: Lmax, maximum increase in bioluminescence from baseline; M, mean value; SD, standard deviation; T50, time
necessary to reach the bioluminescence value Lmax/2.
FIG. 2. Short-term in vivo CCD signal intensity in the liver of BALB/c mice injected with a high dose of AAV-Luc. Male and
female BALB/c mice were injected with AAV serotype 2 expressing luciferase gene, at a dose of 2.5  1011 genome-contain-
ing particles. AAV-Luc was injected intravenously (IV; n  5 males and 5 females) or intrahepatically (IH; n  5 males and 5
females). Subsequent imaging was performed for luciferase expression, using D-luciferin injected intraperitoneally (150 mg/kg)
and starting on day 3 and every week thereafter. Total bioluminescence was quantified and plotted over time. Each dot repre-
sents the decimal logarithm of bioluminescence for each animal at a time point. A solid line shows the mean value of each group;
dashed lines indicate the confidence interval.
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TABLE 2. Lmax AND T50 VALUES FROM BALB/C MICE TRANSFER
WITH 25  1011 VG OF AAV-LUC
Female Male
IV [M (SD)] IH[M (SD)] IV[M (SD)] IH[M (SD)]
Lmax 2.64 (0.036)00 3.63 (0.062)0 3.56 (0.034)0 4.32 (0.183)00
T50 (days) 5.83 (0.00020) 2.15 (0.00062) 5.83 (0.0020) 2.15 (0.00015)
Abbreviations: Lmax, maximum increase of bioluminescence from baseline; M, Mean value; SD,
standard deviation T50, time necessary to reach the bioluminescence value Lmax/2.
FIG. 3. Short-term in vivo CCD signal intensity in the liver of C57BL/6 mice injected with low-dose AAV-Luc. Male and fe-
male C57BL/6 mice were injected with AAV serotype 2 expressing luciferase gene, at a dose of 2.5  1010 genome-containing
particles. AAV-Luc was injected intravenously (IV; n  5 males and 5 females) or intrahepatically (IH; n  6 males and 7 fe-
males). Subsequent imaging was performed for luciferase expression, using D-luciferin injected intraperitoneally (150 mg/kg) and
starting on day 1 and every week thereafter. Total bioluminescence was quantified and plotted over time. Each dot represents the
decimal logarithm of bioluminescence for each animal at a time point. A solid line shows the mean value of each group; dashed
lines indicate the confidence interval.
Because of the large range in luciferase expression, data were
first subjected to logarithmic transformation before analysis.
The logarithmic value of the luciferase expression (L) after
AAV injection was modeled by assuming a saturable absorp-
tion process and a negligible elimination process in the time
frame considered. The background level of bioluminescence
(nonspecific light) was determined by acquiring the light of
mice that had not been injected with luciferin, and was found
to be equal to 4.
L  4 
where Lmax represents the maximum increase in biolumines-
cence from baseline, T50 represents the time necessary to
Lmax  t
T50  t
reach the bioluminescence value Lmax/2, and t represents
time.
Statistical analysis of the various estimated individual pa-
rameters was performed by two-way analysis of variance
(ANOVA) followed by multiple comparison, using the least sig-
nificant difference test (SPSS software; SPSS, Chicago, IL).
The AAV half-life in liver is determined by fitting the long-
term follow-up data to an elimination process, assuming that
the absorption process in this time frame is negligible:
L  Lbasal  eket
where Lbasal represents the bioluminescence value at steady state
and ke is the constant of the elimination process. The elimina-
tion half-life obtained from the estimated individual parameter
ke was compared by Kruskall–Wallis test.
RESULTS
In vivo quantitative analysis of luciferase expression
after AAV-Luc injection in liver
Male and female BALB/c mice were injected with a single
dose of AAV-Luc at 2.5  1010 VG using three different routes
of administration: intravenous (IV; n  8), intraportal (IP; n 
3), and direct injection into the liver (intrahepatic [IH]; n  8).
Whole body imaging was performed from day 1 postinjection
up to day 92 postinjection and luciferase expression was quan-
tified. Bioluminescence data were measured as photons/sec/
cm2/sr and analyzed in a pharmacokinetic model in which the
“drug” is the transcriptionally active double-stranded DNA in-
termediate of the recombinant AAV. The effect of our drug is
measured and represented as the logarithm of the biolumines-
cence value. This parameter is assumed to be proportional to the
quantity of the drug. Quantitative data were fitted to a model of
a saturable absorption process to perform a detailed statistical
analysis (Fig. 1). In this model, we have defined Lmax as the
maximum increase in bioluminescence from baseline and T50 as
the time necessary to reach the bioluminescence value Lmax/2.
The results are summarized in Table 1. Analysis of Lmax and
T50 values from all the animals was performed with nonlinear
mixed effect models. Model development was driven by the
data; the value of the Lmax parameter was affected by both gen-
der and route of administration, whereas T50 was affected only
by the route of administration. Statistical analysis of Lmax and
T50, using the least significant difference (LSD) test with a sig-
nificance level of 0.05, showed that on the basis of Lmax four
groups of animals showed significant differences: (1) IV female
mice, showing the lowest value; (2) IP female mice and (3) IH
female mice and IP and IV male mice, showing lower and
higher intermediate values, respectively; and (4) IH male mice,
showing the highest transgene expression values (Table 1).
The T50 value was affected by route, but was independent of
gender. Therefore, three different subsets of animals could be
distinguished: (1) IV mice, the subset requiring the longest time
to reach this value; (2) IP mice, the intermediate subset; (3) IH
mice, the third subset, expressing the transgene with the fastest
kinetics. The most striking observation from the analysis of this
parameter is the short period of time required to reach T50 af-
ter IH injection (Table 1).
Our data indicate that IH injection clearly improves AAV-
mediated liver transduction in BALB/c mice, using a relatively
low viral dose. To further confirm our observations we tested
the effect of the route of administration, using a higher dose of
virus and a different strain of mouse, C57BL/6. In these stud-
ies we analyzed IH and IV routes of administration.
Male and female BALB/c mice (n  5) were injected IH and
IV with a single dose of AAV-Luc at 2.5  1011 VG. Biolu-
minescence data were measured from day 3 postinjection up to
day 40 postinjection and analyzed as previously described. As
shown in Fig. 2 and Table 2, the differences in Lmax shown by
female mice were reduced, depending on the route of adminis-
tration, when the dose of virus was increased; however, they
were still significant (females: Lmax IH  3.63 versus Lmax
IV  2.64; p  0.05). Regarding T50, as shown in Table 2, the
values are identical to those obtained when using the low dose,
indicating that the kinetics of transgene expression are inde-
pendent of the dose of virus administered.
To analyze the effect of mouse strain on our results, male
and female C57BL/6 mice (n  5) were injected IH and IV with
a single dose of AAV-Luc at 2.5  1010 VG. Bioluminescence
data were measured from day 3 postinjection up to day 37
postinjection and analyzed as previously described. As shown
in Fig. 3 and Table 3, as previously observed, the lowest ex-
pression level was achieved in female mice after IV injection.
IH injection resulted in the highest levels of transgene expres-
sion in both male and female mice, with the luciferase expres-
sion levels of IH female mice becoming equivalent to those of
IV male mice. Regarding the T50 parameter, the kinetics of
transgene expression were faster after IH injection in both
groups; interestingly, T50 values were smaller than in BALB/c
mice after IV and IH injection, indicating faster expression ki-
netics (Table 3).
Comparison of transgene expression when steady 
state levels were reached
Luciferase transgene expression increased over time until steady
state levels were reached approximately 4 weeks after rAAV ad-
ministration in all the groups of female mice. Thereafter there was
stable expression for more than 17 months (Fig. 4) (length of the
study). Lbasal, which is the bioluminescence value at steady state,
and ke, the constant of the elimination process, were calculated for
every group (Table 4). The intensity of the signal slowly declined
over time, and fitting the data to an exponential elimination model
allowed us to determine a median elimination half-life of 31 years
for the IV-injected animals, 55 years for the IP-injected animals
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TABLE 3. Lmax AND T50 VALUES FROM C57BL/6 MICE TRANSFER WITH
2.5  1010 VG OF AAV-Luc
Female Male
IV [M (SD)] IH [M (SD)] IV [M (SD)] IH [M (SD)]
Lmax 2.05 (0.089) 2.93 (0.184) 2.64 (0.135) 3.88 (0.212)
T50 (days) 1.64 (0.121) 0.79 (0.359) 1.90 (0.095) 0.97 (0.445)
Abbreviations: Lmax, maximum increase in bioluminescence from baseline; M, mean
value; SD, standard deviation; T50, time necessary to reach the bioluminescence value
Lmax/2.
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FIG. 4. Long-term in vivo CCD signal
intensity in the liver of BALB/c mice in-
jected with low-dose AAV-Luc. Female
BALB/c mice (n  3) were injected with
AAV serotype 2 expressing luciferase gene
at a dose of 2.5  1010 genome-containing
particles. AAV-Luc was injected IP, IV, 
or IH. Each dot represents the decimal 
logarithm of the bioluminescence value
for each animal at each time point. A solid
line shows the mean value of each group;
dashed lines indicate the confidence in-
terval.
FIG. 5. Bioluminescence imaging of AAV-Luc
gene expression in living mice, using a cooled
CCD camera. Eight-week-old male and female
BALB/c mice were injected with AAV serotype 2
expressing the luciferase gene, at a dose of 2.5 
1010 genome-containing particles and using dif-
ferent routes. The mice were repeatedly scanned
with the CCD camera as described in Fig. 2. Op-
tical CCD images for luciferase expression 96 days
postinjection, once a steady state level of lucifer-
ase expression was reached, are shown. (A) Male
and female mice injected intravenously (IV); (B)
male and female mice injected intraportally (IP);
(C) male and female mice injected intrahepatically
(IH).
and 35 years for the IH-injected animals (Table 4), which means
life-long expression of the transgene in the liver of all animals af-
ter AAV injection. Differences in the half-life value among the
groups were not statistically significant, indicating that the elimi-
nation process does not depend on the route of administration.
Biodistribution of luciferase expression
As shown in Fig. 5, by the time luciferase expression reached
steady state levels in the liver, no luciferase expression could
be detected in other organs independently of the route of ad-
ministration or gender. Furthermore, expression of luciferase
was evenly distributed throughout the entire liver after IV and
IP administration of AAV-Luc (Fig. 5A and B), whereas IH ad-
ministration of the virus resulted in higher expression of lucif-
erase at the site of injection (Fig. 5C).
To confirm and supplement in vivo imaging data, animals
from the first study (BALB/c mice injected with 2.5  1010 VG
of AAV-Luc) were killed 3 months after AAV injection and
whole organ preparations were analyzed ex vivo for luciferase
activity, using a luminometer. To perform the analysis of lu-
ciferase expression, the three major lobes of the liver were ex-
cised: left medial lobe (LML), right medial lobe (RML), and
right lateral lobe (RLL). We also tested luciferase expression
in other organs, such as testicles or ovaries, spleen, stomach,
lungs, heart, kidney, and injected muscle. As shown in Fig. 6,
ex vivo analysis confirmed the findings based on biolumines-
cence image analysis. Luciferase expression after IH injection
was confined mainly to the injected left medial lobe. Expres-
sion in the other lobes was more than 100-fold lower. How-
ever, luciferase expression in the liver of IV- and IP-injected
mice was evenly distributed. Analysis of luciferase expression
in the rest of the organs tested revealed no luciferase expres-
sion after IH injection. Low levels of luciferase expression were
detected in the spleen and heart of male mice given IV injec-
tions (278.60 and 1585.73 RLU/mg of tissue protein, respec-
tively) and in the spleen and kidney of male mice given IP in-
jections (647.71 and 6203.65 RLU/mg of tissue protein,
respectively).
DISCUSSION
We constructed an rAAV vector that expresses luciferase un-
der the transcriptional control of a constitutive promoter to eval-
uate in vivo the effect of the route of administration on AAV-
mediated liver transduction. A detailed and quantitative
long-term in vivo follow-up of the biodistribution of transgene
expression after the administration of rAAV was performed.
The bioluminescence data were analyzed using a pharmacoki-
netic model in which the “drug” was the transcriptionally ac-
tive double-stranded DNA intermediate of the recombinant
AAV and the “effect” of the drug was measured and represented
as the logarithm of the bioluminescence value. This parameter
was assumed to be proportional to the quantity of the drug.
Quantitative data were fitted to a model of a saturable absorp-
tion process to perform a detailed statistical analysis. Our re-
sults show that luciferase expression levels in the liver clearly
depend on the route of AAV administration and the gender of
the animal, whereas the kinetics of AAV-mediated transgene
expression were affected by the route of administration and, in-
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FIG. 6. Ex vivo analysis of luciferase expression in liver
lobes. Female and male BALB/c mice were injected with 2.5 
1010 genome-containing particles of AAV-Luc by three differ-
ent routes (IV, IP, and IH). Ninety-two days later, mice were
killed and three of the hepatic lobes were removed: the left me-
dial lobe (LML) (injected lobe), the right medial lobe (RML),
and the right lateral lobe (RLL). Luciferase expression was tested
in the homogenized tissue, using a luminometer. The y axis in-
dicates the median relative light units (RLU) per milligram of
protein of each group. (A) IV injected animals; (B) IP injected
animals; (C) IH injected animals. After IH injection the injected
lobe showed the highest luciferase expression value (p 	 0.05;
ANOVA); after IV and IP injection luciferase activity was uni-
formly distributed throughout the main hepatic lobes.
TABLE 4. Lbasal AND ke VALUES FROM BALB/c FEMALE MICE TRANSFER WITH
2.5  1010 VG OF AAV-Luc
IV [M (SD)] IP [M (SD)] IH [M (SD)]
Lbasal 5.575 (0.089) 6.377 (0.105) 6.904 (0.046)
ke (years1) 0.0230 (0.020) 0.0081 (0.0151) 0.0195 (0.070)
Abbreviations: Lbasal, bioluminescence value of steady state; M, mean value; SD,
standard deviation; ke, constant of the elimination process.
terestingly, by the strain of mouse and was independent of the
sex. All animals demonstrated life-long luciferase expression
with no evidence of vector silencing or immune response
against the transgene, even though we were using a nonmam-
malian protein.
As previously described (Davidoff et al., 2003; Berraondo
et al., 2005), differences in the magnitude of transgene expres-
sion were found in the liver after IV administration of rAAV-
2, depending on the gender of the animal (Fig. 1). However,
we also found that these differences could be minimized by
modifying the route of administration. Intraportal injection re-
duced the difference from 100-fold to less than 10-fold and IH
injection further reduced the difference to less than 3-fold.
Those results, obtained with a relatively low dose of virus, were
reproduced with a 10-fold higher amount (Fig. 2) and were in-
dependent of the strain of mouse (Fig. 3). Interestingly, IV and
IP injection procedures in male mice resulted in equivalent
transgene expression, whereas IH injection resulted in the high-
est level of transgene expression. Thus IH injection clearly im-
proves liver transduction independently of gender, the dose of
virus, or the strain of mouse.
The mechanism underlying the lower efficiency of AAV-
mediated liver transduction observed in female mice is currently
unknown. Davidoff et al. (2003) suggested that the differences
were due to an androgen-dependent pathway, associated with
the presence of male-specific cellular factors that lead to higher
level of rAAV genomes in male than in female mice. The data
obtained from our study showed that the differences in gene ex-
pression depending on gender were minimized when the virus
was administered by liver-directed injection. These results sug-
gest that increasing the local concentration of rAAV in the liver
might overcome the lack of certain androgen-related factor(s)
or, alternatively, that IH injection induces the expression of
those factors, necessary for the establishment of AAV-medi-
ated transgene expression in females. However, we cannot rule
out the possibility that liver-directed injections might bypass
the inhibitory effect of factors present in the blood of animals.
Furthermore, the analysis of transgene expression in mice
given IH injections showed a faster onset of luciferase expres-
sion in comparison with mice given IV and IP injections. The
rate-limiting steps of AAV transduction efficacy are the rela-
tively slow nuclear import of AAV genomes, the rate of virus
uncoating, and the conversion of ssDNA to transcriptionally
competent double-stranded templates (Alexander et al., 1994;
Ferrari et al., 1996; Bartlett et al., 2000; Chen et al., 2001;
Thomas et al., 2004). In the liver, it has been suggested that ds-
DNA conversion occurs through annealing of complementary
plus and minus single-stranded molecules, not by the de novo
synthesis of the second strand; if this is the case the rate of un-
coating is a key determinant for the ability of complementary
molecules to convert to biologically active molecular forms
(Nakai et al., 2000). IH injection might be associated with faster
entrance of AAV genomes into the nucleus or with a faster un-
coating of vector genomes, which would allow, as in the case
of other pseudotyped vectors (Thomas et al., 2004), a more ef-
ficient formation of AAV double-stranded templates. However,
there is still a certain degree of controversy regarding the mech-
anism of the formation of transcriptionally active forms and
other explanation may be plausible as well (Qing et al., 1998;
Miao et al., 2000; Nakai et al., 2000).
The explanation we favor, on the basis of our observations,
is that intrahepatic injection first reduces the contact of AAV
vectors with inhibitory molecules present in the blood and con-
centrates the virus in the liver. Once in the liver, the virus un-
dergoes faster uncoating (by a mechanism that requires further
studies to be elucidated), resulting in faster formation of tran-
scriptionally active forms.
The in vivo and ex vivo analysis of luciferase expression af-
ter intravenous or intraportal AAV administration showed a
wide distribution throughout the liver and a low level of ex-
pression in some organs in male but not in female mice (data
not shown). This might indicate that the gender dependency de-
tected in the liver also occurs in other organs (Dodge et al.,
2005). After intrahepatic injection, luciferase expression is re-
stricted mostly to the injected hepatic lobe, with low levels of
expression in the other hepatic lobes and nondetectable levels
of expression in the rest of the organs analyzed.
In summary, AAV intrahepatic injection offers several ad-
vantages over other routes of administration: faster transgene
expression, maximum protein expression, and expression con-
fined to the injected hepatic lobe. Finally, direct intrahepatic in-
jection of the virus by ultrasonographic guidance could be eas-
ily performed in humans and in large animals. All these factors
point to the potential of this route of administration for future
clinical applications.
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